======= UBE2G1 =======
== Gene Information ==
* **Official Symbol**: UBE2G1
* **Official Name**: ubiquitin conjugating enzyme E2 G1
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=7326|7326]]
* **UniProt**: [[https://www.uniprot.org/uniprot/P62253|P62253]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=UBE2G1&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20UBE2G1|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/601569|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys- 48'-, as well as 'Lys-63'-linked polyubiquitination. May be involved in degradation of muscle-specific proteins. Mediates polyubiquitination of CYP3A4. {ECO:0000269|PubMed:19103148, ECO:0000269|PubMed:20061386}.
|UQ con|
|protein K63-linked ubiquitination|
|ubiquitin conjugating enzyme activity|
|protein K48-linked ubiquitination|
|ubiquitin-protein transferase activity|
|ubiquitin protein ligase binding|
|protein polyubiquitination|
|proteasome-mediated ubiquitin-dependent protein catabolic process|
|proteasomal protein catabolic process|
|ubiquitin-dependent protein catabolic process|
|modification-dependent protein catabolic process|
|modification-dependent macromolecule catabolic process|
|proteolysis involved in cellular protein catabolic process|
|cellular protein catabolic process|
|protein catabolic process|
|protein ubiquitination|
|protein modification by small protein conjugation|
|cellular macromolecule catabolic process|
|protein modification by small protein conjugation or removal|
|macromolecule catabolic process|
|organonitrogen compound catabolic process|
|proteolysis|
|ATP binding|
|organic substance catabolic process|
|cellular catabolic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|-2.64|
|[[:results:exp410|THZ531 0.11 to 0.125μM on day4 R07 exp410]]|-2.33|
|[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|-2.23|
|[[:results:exp343|Centrinone 0.5μM R07 exp343]]|-2.02|
|[[:results:exp30|Rapamycin 10μM R00 exp30]]|-1.93|
|[[:results:exp444|THZ531 0.225μM R08 exp444]]|-1.88|
|[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|-1.87|
|[[:results:exp233|EPZ-5676 30μM R05 exp233]]|-1.72|
|[[:results:exp102|Nifuroxazide 5μM R03 exp102]]|-1.7|
|[[:results:exp34|Rotenone 20μM R00 exp34]]|1.73|
|[[:results:exp164|Q15 1 to 2μM on day4 R04 exp164]]|1.81|
|[[:results:exp391|Pomalidomide 20μM R07 exp391]]|1.83|
|[[:results:exp33|Rotenone 2μM R00 exp33]]|1.95|
|[[:results:exp417|Tubastatin-A 2.5μM R07 exp417]]|1.99|
|[[:results:exp199|Etoposide 0.3μM R05 exp199]]|2.05|
|[[:results:exp240|Pyridostatin 4μM R05 exp240]]|2.15|
|[[:results:exp245|UM0011500 5μM R05 exp245]]|2.22|
|[[:results:exp198|Etoposide 0.1μM R05 exp198]]|2.3|
|[[:results:exp350|Deferoxamine 11μM R07 exp350]]|2.34|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|2.5|
|[[:results:exp8|Brefeldin A 0.02μM R00 exp8]]|2.62|
|[[:results:exp478|Doxorubicin 0.02μM R08 exp478]]|2.84|
|[[:results:exp106|UM131593 0.2μM R03 exp106]]|3.01|
|[[:results:exp2|5-Fluorouracil 20μM R00 exp2]]|3.54|
|[[:results:exp360|Genistein 15μM R07 exp360]]|3.54|
|[[:results:exp79|Q15 2.7μM R02 exp79]]|3.61|
|[[:results:exp3|Actinomycin-D 0.001μM R00 exp3]]|3.72|
^Gene^Correlation^
|[[:human genes:g:glmn|GLMN]]|0.583|
|[[:human genes:m:mllt1|MLLT1]]|0.552|
|[[:human genes:c:cul4a|CUL4A]]|0.542|
|[[:human genes:h:hars|HARS]]|0.533|
|[[:human genes:t:thoc6|THOC6]]|0.53|
|[[:human genes:f:fkbp5|FKBP5]]|0.526|
|[[:human genes:m:med23|MED23]]|0.473|
|[[:human genes:f:fbxo11|FBXO11]]|0.471|
|[[:human genes:m:med13l|MED13L]]|0.463|
|[[:human genes:t:tle4|TLE4]]|0.455|
|[[:human genes:u:ube3a|UBE3A]]|0.446|
|[[:human genes:m:meaf6|MEAF6]]|0.434|
|[[:human genes:m:med13|MED13]]|0.428|
|[[:human genes:z:znf608|ZNF608]]|0.426|
|[[:human genes:m:mapk14|MAPK14]]|0.425|
|[[:human genes:u:ubr5|UBR5]]|0.42|
|[[:human genes:s:slc38a2|SLC38A2]]|0.411|
|[[:human genes:o:otud5|OTUD5]]|0.403|
|[[:human genes:b:brpf1|BRPF1]]|0.401|
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 8724
* **Expression level (log2 read counts)**: 6.37
{{:chemogenomics:nalm6 dist.png?nolink |}}